Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what steps he is taking to introduce the drug Duodopa for the treatment of NHS patients with Parkinson's disease.

On 2 July 2015, NHS England announced that Duodopa will now be routinely commissioned by NHS England for patients meeting the inclusion criteria agreed by the Neurosciences Clinical Reference Group.

The specific commissioning policy on Duodopa is available here:

http://www.england.nhs.uk/commissioning/spec-services/npc-crg/group-d/d04/

This decision followed a three-month public consultation on the principles and processes NHS England will follow when making investment decisions.